Research use only. Read more

Growth Hormone

IGF1-LR3

A long-acting IGF-1 analog with an extended N-terminal sequence and an arginine substitution that reduces IGF-binding-protein affinity, producing a substantially longer circulating half-life than native IGF-1.

Also known as: Long R3 IGF-1

Quick facts

Molecular weight

9,111 Da

Half-life

24 h

Frequency

daily

Admins / wk

7

Routes

SubQ

Typical dose

20 mcg–50 mcg

Mechanism & positioning

A long-acting IGF-1 analog with an extended N-terminal sequence and an arginine substitution that reduces IGF-binding-protein affinity, producing a substantially longer circulating half-life than native IGF-1.

Researched for: IGF-1 receptor agonism, anabolic signalling.

Reconstitution defaults

Default vial

1 mg

BAC water

1 mL

Concentration

1000 mcg/mL

Doses per vial

~50

Calculate with this peptide

Documented pairwise interactions

  • caution

    IGF1-LR3 + MGF

    Both signal through the IGF-1 receptor; co-administration is uncommon in published research and adds little novel signalling.

References

  • Walenkamp MJ et al., Horm Res, 2008.

Related peptides in the Growth Hormone class

Frequently asked questions about IGF1-LR3

What is the typical research dose range for IGF1-LR3?
IGF1-LR3 is most commonly investigated at 20 mcg–50 mcg per administration, daily. These values reflect documented research-stage protocols and are not medical recommendations.
What is the half-life of IGF1-LR3?
IGF1-LR3 has an approximate plasma half-life of 24 hours. Practical steady state is reached after roughly five half-lives — about 5 days under continuous administration.
How is IGF1-LR3 administered in research protocols?
Published research uses subq administration. Typical reconstitution is 1 mg vial in 1 mL of bacteriostatic water, producing a concentration of 1000 mcg/mL.
What vial sizes are commonly available for IGF1-LR3?
Common stocked vial sizes are 1 mg. The 1 mg vial is the most-used default in published protocols.